botulism immune globulin iv

Action and Spectrum

Actions and spectrum: 

botulism immune globulin intravenous (BIG-IV) is a purified, sterile, and concentrated antibody preparation that is indicated for the treatment of patients with botulism. It contains specific antibodies that can neutralize the botulinum neurotoxin types, which are produced by the bacteria Clostridium botulinum. 

BIG-IV is administered intravenously and works by binding to the botulinum toxin in the bloodstream, preventing it from reaching and affecting the nervous system. The neutralized toxin is then cleared by the body’s immune system. 

Drug Interaction

Adverse Reaction

Frequency not defined 

1-10% 

Peripheral coldness 

Dehydration 

Metabolic acidosis 

Local site reaction 

Neurogenic bladder 

Stridor 

Dyspnea  

Oral candidiasis 

Tachycardia 

CNS agitation 

Hyponatremia 

Decrease in hemoglobin 

Injection site erythema
Decrease in the breath sounds 

LRTI 

Tachypnea 

Infusion rate reactions  

>10% 

Pallor Edema 

Cardiac murmur 

Pyrexia 

Contact dermatitis 

Dysphagia 

Vomiting 

Otitis media 

Rhonchi 

Reduced oxygen saturation 

Rales 

increased in bp 

decreased in bp 

Irritability 

Decreased body temperature 

Erythematous rash 

Loose stools 

Abdominal distension 

Atelectasis 

Nasal congestion 

Cough  

Post marketing Reports 

Retrospective publications revealed safety-related information compatible with the authorised product labelling, and no additional safety-related information was given for BabyBIG. 

Black Box Warning

Black Box Warning: 

There is no black box warning associated with botulism immune globulin IV. 

Contraindication / Caution

Contraindication/Caution: 

Contraindication: 

botulism immune globulin IV is contraindicated in patients with severe allergic reaction to human immunoglobulin products. It should not be used in individuals with selective IgA deficiencies, known antibody against IgA and a history of hypersensitivity.  

Caution: 

• Risk of allergic reactions: botulism Immune globulin IV contains human plasma, and there is a potential risk of an allergic reaction, including anaphylaxis. Patients should be monitored for any signs of an allergic reaction during administration. 
• Thrombosis risk: There is a theoretical risk of thrombosis associated with the use of botulism Immune globulin IV. This is because the product contains high levels of immunoglobulin G (IgG), which can cause increased blood viscosity. Patients at risk of thrombosis, such as those with a history of venous or arterial thrombosis, should be closely monitored during treatment. 
• Interference with serological testing: botulism Immune globulin IV contains antibodies against the toxins produced by Clostridium botulinum, which can interfere with serological testing for botulism. 
• Transmission of infectious agents: botulism Immune globulin IV is made from plasma and may contain infectious agents like viruses and prions, that can cause disease. Nonetheless, patients should be informed of the potential risk of transmission of infectious agents. 
• pregnancy and lactation: There is limited information available on the use of botulism Immune globulin IV in pregnancy and lactation. Healthcare providers should carefully weigh the potential benefits and risks before administering the product to pregnant or lactating women.

Comorbidities: 

There are no known specific comorbidities associated with botulism immune globulin IV. However, it should be used under caution in patients with allergic reactions to human immunoglobulin products, as well as in patients with known thrombotic or embolic disorders 

Pregnancy / Lactation

Pregnancy consideration: US FDA pregnancy category: Not assigned 

Lactation: It is not known whether botulism immune globulin IV is excreted in human milk.  

Pregnancy category: 

• Category A: Satisfactory and well-controlled studies show no risk to the fetus in the first or later trimester. 
• Category B: There is no evidence of risk to the fetus found in animal reproduction studies and there are not enough studies on pregnant women. 
• Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for an effect in humans, care must be taken for potential risks in pregnant women. 
• Category D: There is adequate data available with sufficient evidence of human fetal risk from various platforms, but despite potential risks may be used only in emergency cases for potential benefits. 
• Category X: Drugs listed in this category outweigh risks over benefits These category drugs should be prohibited for pregnant women. 
• Category N: There is no data available for the drug under this category. 

Pharmacology

Pharmacology: 

botulism immune globulin intravenous (BIG-IV) is a purified preparation of human immunoglobulin G (IgG) antibodies that bind to botulinum neurotoxins (BoNTs) and neutralize their effects. BIG-IV contains a mixture of antibodies derived from the plasma of healthy donors who have been immunized with a pentavalent botulinum toxoid vaccine. 

The pharmacology of BIG-IV involves the passive transfer of antibodies to patients with botulism, which bind to circulating BoNTs and prevent them from binding to nerve terminals and inhibiting acetylcholine release. This can reduce the severity and duration of symptoms and improve outcomes in patients with botulism. 

BIG-IV has a half-life of approximately 23 days and is catabolized by the reticuloendothelial system. It does not undergo metabolism or biotransformation and is primarily eliminated by the kidneys.  

Pharmacodynamics: 

The pharmacodynamics of BIG-IV is based on its mechanism of action as an immunoglobulin preparation. When administered, BIG-IV binds to the botulinum toxin in the bloodstream, forming immune complexes that are subsequently cleared from the body by the reticuloendothelial system. 

BIG-IV functions to provide passive immunity to individuals who have been exposed to botulinum toxin, by binding to the toxin and preventing it from binding to neuronal receptors, thereby preventing the release of acetylcholine and blocking the neuromuscular transmission that leads to muscle paralysis. The onset of action is immediate upon administration, and the duration of action is thought to be several weeks.  

Pharmacokinetics: 

Absorption 

BIG-IV is administered intravenously and is fully absorbed. 

Distribution 

The distribution of BIG-IV is limited to the intravascular space due to its large molecular weight. 

Metabolism 

BIG-IV is expected to be catabolized into smaller peptides and amino acids via the same metabolic pathways as endogenous immunoglobulin G (IgG). 

Elimination and excretion 

The elimination half-life of BIG-IV is approximately 21 days. The primary route of elimination is via catabolism in the reticuloendothelial system, primarily in the liver and spleen. 

Adminstartion

Administration: 

botulism immune globulin intravenous (BIG-IV) is administered intravenously (IV) as a single dose. The recommended dosage and infusion rate depend on the patient’s body weight and severity of the disease.

The infusion should be given slowly over 30-60 minutes, and patients should be monitored closely for any adverse reactions during and after the infusion. BIG-IV should only be administered by healthcare professionals trained in the recognition and treatment of severe allergic reactions. 

Patient Information Leaflet

Patient information leaflet 

Generic Name: botulism immune globulin iv 

Pronounced: [ BOT-ue-lizm-im-MYOON-GLOB-yoo-lin ]  

Why do we use botulism immune globulin iv? 

botulism immune globulin intravenous (BIG-IV) is used for the treatment of symptomatic botulism. It is an antitoxin that is used to neutralize the toxins produced by Clostridium botulinum bacteria, which causes botulism. botulism can cause muscle weakness, paralysis, and even death if left untreated. BIG-IV is given as a part of a comprehensive treatment plan that may include supportive care, such as mechanical ventilation and intensive medical management. It is important to note that BIG-IV is not a vaccine and is not used for prevention of botulism.